VN April 2020

Vetnews | April 2020 25 Veterinary Dentistry and Maxillofacial Surgery Referrals Veterinary Dentistry and Maxillofacial Clinic, Private Bag X04, Onderstepoort, 0110 Veterinary Dentistry and Maxillofacial Clinic, Onderstepoort Veterinary Academic Hospital, Faculty of Veterinary Science, University of Pretoria, Old Soutpan Road (M35), Onderstepoort, South Africa Tel: +27 (0)12 529 8276 , Fax: +27 (0) 12 529 8479, e-mail: sadent@mweb.co.za, website: www.vetdentsa.co.za , Facebook: Vetdent SA Regulars I Dental column HISTOLOGY There are three main categories based on microscopic features of the predominant cell type including polygonal (epithelioid), spindle and mixed (epithelioid and spindle) cells. Different studies disagree re distribution of types. Diagnosis A variety of useful antibodies for IHC assays are now available for the diagnosis of canine oral melanoma: S100, Melan A, PNL2 and tyrosinase-related proteins 1 and 2. S100 may be the most sensitive, but it is the least specific of this antibody stains. A novel prognostic indicator in canine oral melanoma, is the evaluation of the marker Ki67; levels above 19.5 have a sensitivity and specificity of 87.1%and 85.4% in predicting death or euthanasia at 1 year post-diagnosis (Bergin, 2011). Other prognostic factors of value are the mitotic index, the percentage of nuclear atypia, and the degree of pigmentation. TREATMENT OPTIONS: a) Curative intent surgery This is the cornerstone of treatment, combined with vaccine/ chemotherapy or radiation therapy. The case series published by Tuohy et al (JAVMA 2014) analysing 70 patients undergoing curative intent surgery described a median progression-free interval (PFI) and survival time (ST) of 508 and 723 days, respectively. Thirty-two (45.7%) dogs had disease progression. Significant associations with PFI or ST were found for administration of adjuvant therapy, presence of metastatic disease at the time of diagnosis, higher tumour stage (III or IV), and increased tumour size (> 3 cm). Co-adjuvant treatment was associated with a 130% increased hazard of disease progression; the presence of metastasis at the time of diagnosis was associated with a 281% increased hazard of death. A second paper (Boston JAVMA 2014) evaluating the efficacy of systemic therapies after surgical excision of oral melanomas indicated that surgical treatment of oral malignant melanoma in dogs can result in a median survival time (MST) of 346 days, with long-term survival in 29% of cases. Dogs that were treated with surgery alone had an MST of 352 days, and we were not able to detect a survival advantage with any form of postoperative adjuvant therapy. Interestingly this paper reported no difference on MST between marginal resections and wide or radical resections. b) Xenogeneic DNA vaccination Vaccine (Oncept in the UK) contains plasmid DNA-targeting tyrosinase, a glycoprotein essential for melanin synthesis and demonstrated to be overexpressed in melanomas (Bergman & Wolchok 2008). Results are conflicting so far but is potentially therapeutic in stage II/III locoregionally controlled disease. Results of Grosenbaug (2011) documented a statistically significant improvement in survival for vaccinates (more than 1075 days) compared to historic controls. Verganti (2017) reported only a disease free interval of 477 days in vaccinated dogs vs 491 for non- vaccinates and a MST of 455 days. In Ottnod’s (2013) study, disease free interval for vaccinates was 171d, and for non vaccinates it was 258 days. In the Verganti (2017) study, effects of vaccine were seen early on (in loading period) but 50% of patients with stages I to III disease died due to local recurrence (with or without regional lymph node involvement; 17·9%) or due to metastatic disease (29·6%) to the lymph nodes, lungs, liver, brain, tonsil and skin which means melanoma vaccine may not be effective in all the patients treated or works only for a limited time. Patients with macroscopic disease had a 44·4% response rate to the vaccine and the MST for dogs with stage IV disease was 178 days. c) Carboplatin: Response rate 28% d) Cisplatin and piroxicam: response rate 18% both drugs nephrotoxic. e) Palliative radiation: MST 7.9 months (prognosis not dependent on stage – they all respond the same) f) Definitive-intent radiation therapy (Proulx 2003) MST 7 months g) Hypofractionated radiation plus low-dose cistin or carboplatin as a radiation sensitiser – MST 363 days. v

RkJQdWJsaXNoZXIy OTc5MDU=